Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer
The purpose of this study is to learn whether it is better to receive the drug Metformin with standard of care for lung cancer or just standard of care.
Checked against the public recordLast updated Mar 10, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Prevention
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Mayo Clinic
- Interventions being studied
- Drug: Metformin; Other: Placebo Comparator
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria * Suspected or biopsy proven Stage IA-IIIA lung squamous cell carcinoma (SCC) (must be proven SCC at the time of surgery) * Medically fit for surgical resection (based on surgeon assessment) * Current or prior smoker * Age \> 18 years old * Both Male and Female * Willing and able to consent to study, undergo study interventions, and take study drug * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2 * Subject must start Metformin within 90 days of surgery. Exclusion Criteria * Currently taking metformin or other diabetic drugs * Current or previous congestive heart failure, renal failure or liver failure * Creatinine in Women of 1.4 or greater and Creatinine in Men of 1.5 or greater * Existing untreated or prior cancer \<5 years from diagnosis * Received neo-adjuvant platinum-based chemotherapy or targeted therapy * Receiving adjuvant platinum-based chemotherapy or targeted therapy after surgical resection
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Mayo Clinic in RochesterRochester, Minnesota
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 10, 2020. Always confirm current availability with the study team.